Abstract
Information on medicinal products is vital for enabling patients to give informed consent to the use of a specific product. Within the European Union (EU) the debate about how much information about prescription-only medicinal products should be made available to patients has gone on for the past five years with no definite conclusion yet. This contribution assesses the current legislation and the ongoing debate in order to identify the challenges and the prospect of new legislation, and consider its potential implications for the scope for advertising and for patient safety.
| Original language | English |
|---|---|
| Journal | European Journal of Health Law |
| Volume | 21 |
| Issue number | 2 |
| Pages (from-to) | 176-195 |
| Number of pages | 20 |
| ISSN | 0929-0273 |
| DOIs | |
| Publication status | Published - 2014 |